Margetuximab Versus Trastuzumab in Patients With Previously Treated HER2-Positive Advanced Breast Cancer (SOPHIA): Final Overall Survival Results From a Randomized Phase 3 Trial
MacroGenics
Hope S Rugo; Seock-Ah Im; Fatima Cardoso; Javier Cortes; Giuseppe Curigliano; Antonino Musolino; Mark D Pegram; Thomas Bachelot; Gail S Wright; Cristina Saura; Santiago Escrivá-de-Romaní; Michelino De Laurentiis; Gary N Schwartz; Timothy J Pluard; Francesco Ricci; William R Gwin; Christelle Levy; Ursa Brown-Glaberman; Jean-Marc Ferrero; Maaike de Boer; Sung-Bae Kim; Katarína Petráková; Denise A Yardley; Orit Freedman; Erik H Jakobsen; Einav Nili Gal-Yam; Rinat Yerushalmi; Peter A Fasching; Peter A Kaufman; Emily J Ashley; Raul Perez-Olle; Shengyan Hong; Minori Koshiji Rosales; William J Gradishar; SOPHIA Study Group